

## MEDIA RELEASE

### Molecular Partners to Present at HC Wainwright and Morgan Stanley Healthcare Conferences

**Zurich-Schlieren, Switzerland, September 11, 2020.** [Molecular Partners AG](#) (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that Patrick Amstutz, chief executive officer, will be presenting at the HC Wainwright 22<sup>nd</sup> Annual Global Investments Conference taking place September 14-16, 2020, as well as participating in a fireside chat at the Morgan Stanley Global Healthcare Conference taking place September 14-18, 2020.

Details for the presentations are as follows:

#### **HC Wainwright 22nd Annual Global Investments Conference**

Presentation Date: Monday, September 14, 2020

Presentation Time: 11:30 a.m. ET

#### **Morgan Stanley Global Healthcare Conference**

Presentation Date: Wednesday, September 16, 2020

Presentation Time: 1:15 p.m. ET

A webcast of the presentations will be available on the [Molecular Partners website](#).

#### **About Molecular Partners AG**

Molecular Partners AG is a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, designed to address challenges current modalities cannot. The Company has compounds in various stages of clinical and preclinical development with a focus on oncology. Molecular Partners has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics across multiple therapeutic areas.

For more information regarding Molecular Partners AG, go to: [www.molecularpartners.com](http://www.molecularpartners.com)

#### **For further details, please contact:**

Seth Lewis, SVP IR, Comms & Strategy

[seth.lewis@molecularpartners.com](mailto:seth.lewis@molecularpartners.com)

Tel: +1 781 420 2361

Tom Donovan, U.S. Media

[tom@tenbridgecommunications.com](mailto:tom@tenbridgecommunications.com)

Tel: +1 857 559 3397

Thomas Schneckeburger, IR & European Media

[thomas.schneckeburger@molecularpartners.com](mailto:thomas.schneckeburger@molecularpartners.com)

Tel: +41 79 407 9952